GlassScriptPhysician profile
Robert Lewis Pugh
NPI 1407814791
$1,287.84
in general payments reported to CMS, 2019-2025
28 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $159 · 2021: $153 · 2022: $280 · 2023: $263 · 2024: $87.55 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $588.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $407.78 | 2022-2023 | Qelbree |
| Novo Nordisk INC | $123.07 | 2025 | Ozempic |
| Xeris Pharmaceuticals, INC. | $92.23 | 2024-2025 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $53.20 | 2020 | |
| Amarin Pharma, INC. | $50.47 | 2020 | |
| Antares Pharma, INC. | $48.78 | 2021-2022 | |
| Lilly USA, LLC | $41.17 | 2021-2023 | Trulicity, Mounjaro |
| Glaxosmithkline, LLC. | $36.89 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $36.44 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $35.23 | 2021-2025 | Belbuca |
| Abbvie INC. | $34.86 | 2021-2025 | |
| Philips North America LLC | $33.52 | 2019-2020 | |
| Exact Sciences Corporation | $32.72 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $31.06 | 2019 | |
| Zyla Life Sciences, INC. | $27.37 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $25.43 | 2022 | |
| Genentech USA, INC. | $18.68 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $18.43 | 2021 | |
| Almatica Pharma LLC | $17.34 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.44 | 2025 | Caplyta |
| Pfizer INC. | $15.88 | 2023 | |
| Astellas Pharma US INC | $15.06 | 2019 | |
| Amgen INC. | $14.95 | 2025 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $13.07 | 2019 | |
| Indivior INC. | $12.77 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.91 | 2019 | |
| Irhythm Technologies, INC. | $11.80 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.29 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.